Exelixis

Exelixis company information, Employees & Contact Information

Explore related pages

Related company profiles:

Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat. After operating in the challenging biotech sector for nearly three decades, we've evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. Cancer is our cause. Make it yours, too. Please see our Community Guidelines: bit.ly/4iBzJU0 For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Company Details

Employees
1.50K
Founded
-
Address
1851 Harbor Bay Pkwy, Alameda,california 94502,united States
Phone
6508378300
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Alameda, California
Looking for a particular Exelixis employee's phone or email?

Exelixis Questions

News

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Business Wire

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 Business Wire

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Yahoo Finance

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors Yahoo Finance

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet - Business Wire

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet Business Wire

STELLAR-303 trial: Zanzalintinib+Atezo improve OS in mCRC - Oncodaily

STELLAR-303 trial: Zanzalintinib+Atezo improve OS in mCRC Oncodaily

Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development - The AI Journal

Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development The AI Journal

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer - Yahoo Finance

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer Yahoo Finance

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX - Business Wire

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX Business Wire

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - Yahoo Finance

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 Yahoo Finance

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Business Wire

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update Business Wire

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September - Business Wire

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September Business Wire

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update - Business Wire

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update Business Wire

(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire

(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors Business Wire

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update - Business Wire

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update Business Wire

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 - Yahoo Finance

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 Yahoo Finance

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - Business Wire

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 Business Wire

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 - Business Wire

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 Business Wire

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Yahoo Finance

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Yahoo Finance

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November - FinancialContent

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November FinancialContent

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor - Business Wire

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor Business Wire

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline - Business Wire

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline Business Wire

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes - Business Wire

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes Business Wire

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies - Business Wire

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies Business Wire

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology - Business Wire

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology Business Wire

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023 - FinancialContent

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023 FinancialContent

Silicon Valley - FinancialContent

Silicon Valley FinancialContent

Exelixis Statement on the Passing of Two Senior Executives - FinancialContent

Exelixis Statement on the Passing of Two Senior Executives FinancialContent

Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 - FinancialContent

Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 FinancialContent

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September - FinancialContent

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September FinancialContent

Exelixis Announces $550 Million Share Repurchase Program - FinancialContent

Exelixis Announces $550 Million Share Repurchase Program FinancialContent

Silicon Valley - FinancialContent

Silicon Valley FinancialContent

Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021 - FinancialContent

Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021 FinancialContent

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September - FinancialContent

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September FinancialContent

Silicon Valley - FinancialContent

Silicon Valley FinancialContent

Silicon Valley - FinancialContent

Silicon Valley FinancialContent

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology - FinancialContent

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology FinancialContent

Silicon Valley - FinancialContent

Silicon Valley FinancialContent

Silicon Valley - FinancialContent

Silicon Valley FinancialContent

Silicon Valley - FinancialContent

Silicon Valley FinancialContent

Top Exelixis Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant